APO-KETOROLAC INJECTABLE 30 MG — DIN 02243989
KETOROLAC TROMETHAMINE : 30 MG · APOTEX INC · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is APO-KETOROLAC INJECTABLE?
APO-KETOROLAC INJECTABLE 30 MG contains KETOROLAC TROMETHAMINE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02243989, held by APOTEX INC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as dormant, status dated 04-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How much does Ketorolac cost around the world?
Ketorolac is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 5 | 53 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 10 | 12 | EUR███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
80 pack listings across 30 brand entries and 7 price bases, refreshed 05 Sep 2026. Ranges span every Ketorolac pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ketorolac in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
21 holders have a Canadian DIN containing Ketorolac, across 25 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 2 | 1 | APO-KETOROLAC, APO-KETOROLAC INJECTABLE | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 2 | 1 | KETOROLAC TROMETHAMINE INJECTION, USP | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP KETOROLAC, KETOROLAC TROMETHAMINE INJECTION USP | Sourceable in Canada |
| AA PHARMA INC | 1 | 1 | TORADOL | Sourceable in Canada |
| ATNAHS PHARMA UK LIMITED | 1 | 1 | TORADOL IM | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 1 | 1 | KETOROLAC TROMETHAMINE INJECTION, USP | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | MAR-KETOROLAC | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-KETOROLAC | Sourceable in Canada |
| SYNTEX INC. | 2 | 0 | TORADOL INJ 10MG/ML, TORADOL TAB 10MG | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | RIVA-KETOROLAC 10 MG | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | NOVO-KETOROLAC - TAB 10MG | No marketed DIN |
| WAYMADE PLC | 1 | 0 | WAYMADE-KETOROLAC TROMETHAMINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Ketorolac |
|---|---|
| ATC code | M01AB15 |
| AHFS class | 84:04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243989 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243989 |
| Brand name | APO-KETOROLAC INJECTABLE |
| Generic / active ingredient | KETOROLAC TROMETHAMINE : 30 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | M01AB15 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01AB |
| Current status | DORMANT |
| Status date | 04-Aug-2017 |
| Original market date | 2001-08-23 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Ketorolac in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by AA PHARMA INC (Tier 3 Drug Shortages About & Resources), last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-KETOROLAC | 10 MG | TABLET | APOTEX INC | MARKETED | 02229080 |
| JAMP KETOROLAC | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02510855 |
| KETOROLAC TROMETHAMINE INJECTION, USP | 30 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | 02443376 |
| KETOROLAC TROMETHAMINE INJECTION, USP | 30 MG | LIQUID | FRESENIUS KABI CANADA LTD | MARKETED | 02244947 |
| MAR-KETOROLAC | 10 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02465124 |
| MINT-KETOROLAC | 10 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02461455 |
| TORADOL | 10 MG | TABLET | AA PHARMA INC | MARKETED | 02162660 |
| TORADOL IM | 10 MG | SOLUTION | ATNAHS PHARMA UK LIMITED | MARKETED | 02162644 |
| KETOROLAC TROMETHAMINE INJECTION USP | 30 MG | SOLUTION | STERIMAX INC | APPROVED | 02461129 |
| KETOROLAC TROMETHAMINE INJECTION USP | 30 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02239944 |
2 · Same class — other molecules in ATC M01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diclofenac | APO-DICLO · APO-DICLO RAPIDE 50 MG TABLETS · APO-DICLO SR · AVA-DICLOFENAC · +44 more | 74 | 15 | Yes |
| Ketorolac | APO-KETOROLAC · APO-KETOROLAC INJECTABLE · JAMP KETOROLAC · KETOROLAC TROMETHAMINE INJECTION USP · +12 more | 25 | 8 | Yes |
| Indometacin | APO-INDOMETHACIN · AURO-INDOMETHACIN · FTP-INDOMETHACIN · INDOCID CAP 25MG · +18 more | 31 | 7 | Yes |
| Diclofenac, Combinations | ACT DICLO-MISO · ARTHROTEC 50 · ARTHROTEC 75 · DICLOFENAC MISOPROSTOL · +4 more | 12 | 6 | Yes |
| Sulindac | APO-SULIN TAB 150MG · APO-SULIN TAB 200MG · CLINORIL TAB 150MG · CLINORIL TAB 200MG · +6 more | 12 | 2 | Yes |
| Etodolac | ETODOLAC · GEN-ETODOLAC 200MG · GEN-ETODOLAC 300MG · NOVO-ETODOLAC 200 MG · +5 more | 12 | 0 | Not in Canada |
| Tolmetin | NOVO-TOLMETIN CAPSULES 400MG · TOLECTIN 200 TAB 200MG · TOLECTIN 400 CAP 400MG · TOLECTIN TAB 600MG | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M01AE | Fenoprofen · Flurbiprofen · Ibuprofen · Ibuprofen, Combinations · Ketoprofen · +5 more | 398 | 101 |
| M01AH | Celecoxib · Rofecoxib | 72 | 30 |
| M01AC | Meloxicam · Piroxicam · Tenoxicam | 67 | 14 |
| M01AG | Mefenamic Acid | 7 | 1 |
| M01AX | Nabumetone | 12 | 1 |
| M01AA | Oxyphenbutazone · Phenylbutazone · Phenylbutazone, Combinations | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-KETOROLAC INJECTABLE called?
The same molecule, Ketorolac, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ACULAR | Latin | Morocco |
| Acular Augentropf. | Latin | Austria |
| Tora-Dol | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.